Venetoclax combinations in mutant AML subtypes: IDH1/2

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combinations in patients with AML with IDH1/2 mutations.

Clinical studies evaluating the combination of venetoclax + azacitidine versus azacitidine alone have shown that patients with AML with IDH1/2 mutations treated with venetoclax + azacitidine achieved higher response rates, and had better outcomes, compared with patients treated with azacitidine alone.

In this podcast, Pollyea discusses the results of a study further evaluating the efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with AML with IDH1/2 mutations unfit for intensive treatment. Data were combined from two different studies: a phase Ib study where patients were treated with venetoclax + azacitidine and the VIALE-A study (NCT02993523) comparing patients treated with venetoclax + azacitidine versus placebo + azacitidine.

Hosted on Acast. See acast.com/privacy for more information.